Miller will be responsible for all activities of Zynex NeuroDiagnostic, which includes the development and marketing of neurological diagnosis devices to hospitals and clinics worldwide through the utilization of diagnostic EMG (electromyography) technology.
Miller has over 30 years of executive management experience in the global healthcare market with specific expertise in neurostimulation, ultrasound imaging, infusion therapy and point-of-care diagnostics.
He recently served as president of Otomedicine, as well as president of Boston Scientific’s auditory division and president of Cochlear Corporation. His experiences also include senior executive positions with companies such as Johnson and Johnson, Procter and Gamble, Diametrics, IMED and Advanced Technology Laboratories.
Zynex CEO Thomas Sandgaard said since the creation of Zynex NeuroDiagnostic in April 2010, they have worked diligently to further develop and commercialize the company’s proprietary EMG technology, which has been leveraged from their existing NeuroMove product.
"Our long-term goal is to have this subsidiary contribute significantly to the revenue and profit already being generated in Zynex Medical with our line of electrotherapy products," Sandgaard said.
Zynex manufactures, markets and sells its own design of medical devices in three subsidiaries. Zynex Medical is a provider of electrotherapy products for home use, Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals and Zynex NeuroDiagnostic develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets.
